TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: CT 327 in the Treatment of Atopic Dermatitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and Female subjects aged \>18 year~* Written informed consent~* Mild to moderate AD at baseline (EASI score of at least 2 or 3)~* Active AD (visible eczema, erythema and pruritus)~* Presence of at least four target lesions (symmetrically) at inclusion (ideally at the elbow flexions and knee bends)~Exclusion Criteria:~* If female of childbearing potential not using an adequate and appropriate form of contraception such as oral contraceptive; intra-uterine device (IUD); contraceptive injection, implant or patch~* If female, are pregnant or lactating, or intend to become pregnant during the study period~* Allergy to test drug or excipients~* Usage of topical corticosteroids or other topical treatments for AD within the last two weeks prior to study entry (including calcineurin inhibitor, topical H1 and H2 antihistamines, topical antimicrobials, other medicated topical agents) or herbal preparation to the area selected for treatment~* Within 4 weeks prior to study entry, have received systemic treatment for atopic dermatitis (including systemic corticosteroids, nonsteroidals, immunosuppressants, or immunomodulating drugs, or treatment with light).~* Presence of major medical illness requiring systemic therapy including cancers~* Clinical diagnosis of bacterial infection of the skin including impetigo and abscesses~* Any clinical relevant ECG abnormality~* Have any clinically significant abnormal clinical laboratory test results at screening~* Received any investigational drug or taking part in any clinical study within three months prior to this study~* History of drug, alcohol or other substance abuse or other factors limiting the ability to co-operate and to comply with this protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo only (Type: PLACEBO_COMPARATOR): Subjects will apply placebo cream to all 4 target lesions
- Active plus placebo (Type: ACTIVE_COMPARATOR): Subjects will receive CT 327 on 2 of 4 target lesions located on one side of their body. On the remaining 2 target lesions on the other side of their body, placebo will be applied.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Esmolol for the Treatment of Hypertension After Intracerebral Hemorrhage Study (ETHICHS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Signature of the TCLE by participant or companion.~2. Spontaneous intracerebral hemorrhage confirmed by computed tomography or magnetic resonance imaging and fit to be included in the study and initiate therapy with study medications within 6 hours after the event.~3. Intracerebral hemorrhage (volume \< 30 cm3).~4. No immediate surgical indication.~5. Both sexes, aged above 18 years.~6. Systolic blood pressure (\> 150 mmHg and \< 220 mmHg) measured on two occasions with a minimum difference of 2 minutes.~Exclusion Criteria:~1. Cerebral hemorrhage secondary to structural lesions in the brain, vascular malformations, coagulopathies or traumatic brain injury, if known at the time of randomization.~2. Participant in deep coma, defined by the Glasgow Coma Scale score of 3 to 5.~3. Uncontrolled asthmatic or COPD participants, if known at the time of randomization.~4. Participants with Grade IV Heart Failure, defined as heart rate \< 50 beats per minute.~5. Previous hemorrhagic stroke, if known at the time of randomization~6. Participants with Cerebral Vascular Stroke.~7. Participants who have presented previous ischemic cerebrovascular accident, if known at the time of randomization.~8. Chronic diseases with life expectancy less than 3 months.~9. Score ≥ 4 on the ICH score at the time of recruitment.~10. In use of anticoagulants in the last 48 hours, if known at the time of randomization.~11. Patients with contraindication to any of the study medications.~12. Intubation Orotraqueal on arrival at the service.~13. Pheochromocytoma, if known at the time of randomization.~14. Patients with hyperthyroidism, if known at the time of randomization.~15. Known pregnancy or breastfeeding . At the discretion of the investigator, an examination for confirmation may be requested.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Brevibloc, 10 Mg/mL Intravenous Solution (Type: EXPERIMENTAL): 10 mL/h every 5 minutes until reaching the pressure target
- Nitroprusside, Sodium (Type: ACTIVE_COMPARATOR): 0.5 mcg / kg / min every 3 minutes until reaching the pressure target

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Prolonged Monitoring to Detect Ventricular Arrhythmias in Presymptomatic Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Identification of a pathogenic mutation† categorized as associated or probably associated with ARVC~2. Failure to meet definite revised Task Force Criteria for ARVC. Mutation carriers by definition have a major criterion, so included patients may have 1 minor criteria, but would meet Task Force Criteria for ARVC with 2 minor criteria or 1 major criterion.~3. \< 200 PVCs / hour on screening Holter monitor~4. Age \> 2 years~Exclusion Criteria:~1. Implantable device in place (pacemaker, ICD)~2. Age \< 2 years~3. Mutation represents a variant of unknown significance with reasonable probability that it may not be disease causing~4. Non-sustained ventricular tachycardia on screening Holter monitor (≥8 beats \> 100 bpm) and/or ≥ 200 PVCs / hour~5. Previous syncope or palpitations attributed to ARVC by the site investigator~6. Meets definite revised Task Force Criteria for ARVC (≥2 minor criteria and/or ≥1 additional major criterion). These ARVC patients who do not have an implanted device (ICD or pacemaker) will be included in a parallel voluntary registry separate from the study.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Presymptomatic ARVC gene carriers (Type: None): ARVC gene positive patients without manifest ARVC after standard screening clinical testing.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of Mind-Body Interventions for Frequent Attendees Suffering From Medically Unexplained Symptoms (MUS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men or women~* Age 18 or higher~* Treated at the Functional Neurology clinic at Soroka UMC~Exclusion Criteria:~* patients with chronic illness such as cancer, dialysis patients, or any other severe identified illness~* patients who do not speak Hebrew~* bedridden patients~* Schizophrenia, dementia and other severe mental illness

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intervention Group for Prospective Study (Type: EXPERIMENTAL): Intervention: Medical and psychological treatment at the Soroka UMC functional neurology outpatient clinic. Treatment will be conducted by a multidisciplinary staff. Patients will undergo an initial meeting with a neurologist and afterwards will be directed to other members of the team (psychologist, physical therapist) on a case by case basis.
- No Intervention (Type: NO_INTERVENTION): Patient records will be analyzed via Clalit Health Service electronic records. No additional intervention will occur

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Investigation to Evaluate Performance and Safety of RemovAid ™ in Removal of Contraceptive Implants

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Female age 18 or older~* Willing to remove a palpable subdermal Implanon/ Nexplanon CI~* Willing and able to give written informed consent for participation in the investigation~* Willing to provide follow-up information according to the Clinical Investigators brochure~Exclusion Criteria:~* Known allergy to local anaesthetic (lidocaine/lignocaine) or disinfectant (chlorhexidine).~* Active skin lesion over the CI.~* The Investigator considers the subject unlikely to comply with investigational procedures, restrictions and requirements.~* Any contraindication for removal of the PI, as judged by the Investigator.~* Any disorders or medications that might affect coagulation, as judged by the Investigator.~* Any conditions suspected to affect healing or increase risk of infection (e.g. keloid tendency, diabetes or any upper arm dermatological condition that may affect upper arm healing)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- RemovAid arm (Type: EXPERIMENTAL): RemovAid arm -~All subjects have their implant removed by the RemovAid device

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Sage Tablets Compared to Placebo in Menopausal Patients With Hot Flushes and Sweating

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Menopausal since ≥ 1 year~* ≥ 5 hot flushes /24 hours~* Hyperhidrosis Scale score ≥ 2~Exclusion Criteria:~* Affections like asthma, COPD, depression, diabetes, epilepsy, hyper- and hypothyreosis, malign tumours

- Gender: FEMALE
- Minimum Age: 50 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Sage tablets (Type: EXPERIMENTAL): Sage extract, 3400 mg , DER 1:17, in once daily application over 12 weeks treatment phase
- Placebo (Type: PLACEBO_COMPARATOR): Placebo, matching the verum in size and appearance, in once daily application over 12 weeks treatment phase

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Intralesional Tolerogenic Dendritic Cells in Crohn's Disease Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Confirmed diagnosis of Crohn's disease ( Lennard -Jones criteria )~2. Active Crohn's disease in the last six months to the inclusion defined as : CDAI? 220 and endoscopic or radiological criteria of activity~3. Refractory or intolerance to conventional therapy including corticosteroids , immunomodulators and anti-tumor necrosis factor-alpha~4. Presence of visible lesions by endoscopy~5. Acceptance to participate in the study and written informed consent~Exclusion Criteria:~1. No injuries in pre-screening resonance~2. Pregnancy, lactation or women of childbearing age not taking appropriate contraceptive measures~3. Patients HIV + and Hepatitis C Virus + Hepatitis B Virus +~4. Serious concomitant disease:~   * Renal failure with creatinine clearance \< 40ml / min~  * Heart disease: congestive heart failure with ejection fraction \< 45 % , atrial fibrillation treated with oral anticoagulants, uncontrolled ventricular arrhythmias , pericarditis , pleural effusion with hemodynamic~  * Neoplasms or myelodysplasia~  * Psychiatric disorders including alcohol and drugs~5. Symptoms attributable to fibrotic strictures in Crohn's disease at the discretion of the investigators~6. Diarrhea attributable to  short bowel syndrome~7. Active infection , including tuberculosis~8. Participation in research studies of new drugs in the 3 months prior to inclusion.~9. Vaccination with live/attenuated germs in the previous 3 months~10. Personal history of cancer (active or complete remission) or known family history of hereditary cancer.~11. Patients in whom , after observation of the state of their veins , these are considered inaccessible and impossible to perform apheresis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 10 millions dose (Type: EXPERIMENTAL): a total of 10 millions tolerogenic dendritic cells
- 100 millions dose (Type: EXPERIMENTAL): a total of 100 millions tolerogenic dendritic cells

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: IV Acetaminophen vs IV Morphine for Pain Control in Pregnant Women

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~Group 1. We will include pregnant women greater than 24 weeks of pregnancy who present with uterine contractions, but are not in labor and who are warranting treatment with intravenous medication for pain control as part of their routine treatment. This will be defined as the presence of uterine contractions documented on the tocodynamometer. However, the cervix remains less than 2 cm dilated and has not changed after 1 hour after re-examining her cervix.\[23\]~Group 2. We will include pregnant women greater than 34 weeks of pregnancy who present with uterine contractions and are in the first stage of labor and who are warranting treatment with intravenous medication for pain control as part of their routine treatment. This will be defined as the presence of uterine contractions documented on the tocodynamometer and cervical dilation greater than 2 cm, but less than 6 cm. \[23\]~Group 3. We will include pregnant women greater than 16 weeks of pregnancy who present with pain due to a maternal medical condition including sickle cell crisis, pyelonephritis, pancreatitis, cholecystitis, nephrolithiasis or headache and who are warranting treatment with intravenous medication for pain control as part of their routine treatment.~Exclusion criteria:~We will exclude women less than 18 years of age, less than 16 weeks gestation, with weight less than 50 kg, and contraindications to acetaminophen including reported elevated liver function tests, hepatic injury, hepatic disorder, active liver disease, alcoholism, chronic malnutrition, known coagulopathy, hemorrhage, creatinine \> 1.0, or known allergy or hypersensitivity to acetaminophen. We will also exclude women who have received any opioids within the last 24 hours.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- IV Acetaminophen (Type: EXPERIMENTAL): IV acetaminophen for pain control
- IV morphine (Type: ACTIVE_COMPARATOR): IV morphine for pain control

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Single-centre Study of Entonox Versus Midazolam Sedation in Gastroscopy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male/female aged 18 years or over~* Confirmed clinical requirement to undergo diagnostic gastroscopy~* Suitable for sedation~* Able to provide informed consent~Exclusion Criteria:~* History of chronic respiratory or significant cardiac disease~* Requirement for longer procedure eg Barrett's surveillance~* Previous known adverse reaction to Entonox~* Entonox use in previous 4 days~* Known current vitamin B12 or folate deficiency~* Unable to provide consent~* Any known contraindication to Entonox:~* Gas trapped in a part of the body where its expansion may be dangerous, such as air lodged in an artery or artificial traumatic or spontaneous pneumothorax (collapsed lung).~* Decompression sickness (the bends) or following a recent dive~* Air encephalography~* Severe bullous emphysema~* Myringoplasty~* Gross abdominal distension~* Recent severe injuries to the face and jaw~* Current or recent head injuries~* If the patient has recently had any eye surgery where injections of gas have been used

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Midazolam (Type: ACTIVE_COMPARATOR): midazolam sedation combined with pharyngeal anaesthesia~Participants randomized to receive midazolam will have an intravenous cannula sited and, following the administration of xylocaine throat spray as above, will be put into the left lateral position. They will then be given up to 5mg midazolam as appropriate to achieve conscious sedation as for standard protocol in endoscopy.
- Entonox (Type: EXPERIMENTAL): Entonox combined with pharyngeal anaesthesia.~Pharyngeal anaesthesia, given as 8-16 sprays of xylocaine to the pharynx; 3 minutes will be given to allow the pharynx to become anaesthetized.~Participants randomized to receive Entonox will be given the 50:50 nitrous oxide:oxygen mix via a mouthpiece with a demand valve system, once in position for the procedure. Inhalations will be given for 3-5 minutes (or until the participant feels adequately sedated) measured using a stopwatch. Oxygen will be given at 2 litres per minute via nasal cannulae during the procedure, (standard care for sedated procedures). The endoscopist will then proceed to intubate the cricopharynx and perform the procedure in the standard manner.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The isCGM Use and Hypoglycemic Episodes and Fear of Hypoglycemia in Newly Diagnosed Type 1 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Newly diagnosed type 1 diabetes (diagnosed based on the WHO criteria) no later than 6 months after the diagnosis.~* Insulin therapy: multiple daily injections,~* In the investigator's opinion, the participant must be technically capable of using the FreeStyle Libre system~Exclusion Criteria:~* Current or past use of any continuous glucose monitoring system.~* Pump therapy.~* Known allergy to medical adhesives.~* Oral steroid therapy.~* Pregnancy or planning pregnancy within the study duration.~* Breast feeding.~* Dialysis treatment.~* Having a pacemaker.~* Unstable coronary heart disease.~* Cystic fibrosis.~* Cancer.~* Psychiatric disorders.~* Severe end-organ damage (kidney, liver, etc) or any uncontrolled disorder.~* Hospitalization for any reason other than the newly diagnosed type 1 diabetes 6 months prior to inclusion.~* Participating in another clinical trial that could affect glucose measurements or glucose management.~* In the investigator's opinion, if the participant is considered unsuitable for inclusion in the study for any other reason.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: f

Study Arms:
- FreeStyle Libre (Type: EXPERIMENTAL): FreeStyle Libre for 4 weeks.~All subjects will wear a masked sensor (FreeStyle Libre Pro) for 14 days prior to randomisation.
- SMBG (Type: ACTIVE_COMPARATOR): Subjects randomised to the control group will monitor their blood glucose with standard blood glucose meters.~A 14-day FreeStyle Libre Pro is included for these subjects from day 14 to day 28 to collect glycaemic data for comparison to the intervention group of the study.~All subjects will wear a masked sensor (FreeStyle Libre Pro) for 14 days prior to randomisation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetics, Pharmacodynamics and Safety Evaluation of SAR279356 in Intensive Care Unit Mechanically Ventilated Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria :~* ICU patients on mechanical ventilation at the time of randomization~* Patients or legally authorized representative (LAR) giving written informed consent.~Exclusion criteria:~* Patients \<18 years of age;~* Documented Pseudomonas infection or colonization in the last 30 days;~* Immunocompromised patients~* Hypersensitivity to the study drug and/or to prior therapy with monoclonal antibodies;~* Patient who has taken other investigational drugs or prohibited therapy for this study within 1 month or 5 half-lives, whichever is longer;~* Patient or LAR who withdraws consent during the screening (starting from signed informed consent form);~* Acute liver injury related criteria at the time of study entry:~* Pregnant or breast-feeding women~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SAR279356 dose 1 (Type: EXPERIMENTAL): SAR279356 dose 1, single administration
- SAR279356 dose 2 (Type: EXPERIMENTAL): SAR279356 dose 2, single administration
- Placebo (Type: PLACEBO_COMPARATOR): Matching placebo, single administration

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues